Skip to main content
Premium Trial:

Request an Annual Quote

Parke-Davis Signs Deal to Use Genzyme Division's Technology

Premium

FRAMINGHAM, Mass.--Genzyme Molecular Oncology here could earn more than $9 million from a new service and option-to-license agreement it has signed that allows Parke-Davis to use the company's proprietary Sage technology in gene expression studies. Parke-Davis may choose to license Sage for its internal genomics research programs. Initially, the technology will be used in a pharmacogenomics study to analyze gene expression changes in tissue following exposure to potential new drugs.

"SAGE is one of a growing list of genomics technologies Parke-Davis is employing in its drug discovery programs," commented Leonard Post, the company's vice-president of discovery research "We expect SAGE to provide information valuable to many aspects of the discovery and development process."

A high-efficiency, high-throughput method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time, SAGE can be used in many applications to identify disease-related genes, analyze the effect of drugs on tissues, and provide insight into disease pathways, according to the Genzyme subsidiary. It works by isolating short bits of genetic information from expressed genes that are present in the cell being studied. Known as Sage tags, these short sequences, are linked together for efficient sequencing. The resulting data are then analyzed using Sage software to identify each gene expressed in the cell and the levels at which they are expressed, creating a library that can be used to analyze the differences in gene expression between cells.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.